Dosing by Post-Natal Age
0-7 days>7 days20 mg/kg/dose IV q12h20 mg/kg/dose IV q8h
40 mg/kg/dose IV q8h
Including Haematology/Oncology and HPCT patients with fever20 mg/kg/dose IV q8h Dose limit: 1 g/dose; 3 g/day
Meningitis, Cystic Fibrosis respiratory tract infection40mg/kg/dose IV q8h Dose limit: 2 g/dose; 6 g/day
MildModerateSevereDialysisStandard dose, given q12h50% dose given q12h50% dose given q24hDose after dialysis
An Automatic Stop Date of 72 hours is in placeProlonged therapy requires ID or Antimicrobial Stewardship approval
Patients with severe infections (eg, meningitis, brain abscess, pneumonia, sepsis) caused by bacteria with proven resistance to all other antibioticsAcute exacerbation of pulmonary disease in patients with cystic fibrosis who are colonized with multi-drug resistant P. aeruginosa or B. cepacia
Haematology/Oncology and HPCT patients with fever who deteriorate or have identified risk factors
Prevention of emerging resistant organismsHigh costConsider piperacillin-tazobactam, tobramycin, ciprofloxacin, or ceftriaxone/ceftazidime instead
Highly restricted
Severe infections including meningitis, unstable neutropenic patients with fever, and for definitive therapy of infections caused by resistant pathogens
Periodic renal, hepatic, and hematologic function tests
Observe for changes in bowel frequency
Monitor for signs of anaphylaxis during first dose
Meropenem will decrease valproic acid plasma levels. Monitor valproic acid levels and consider alternate anticonvulsants
Incompatible with IV ciprofloxacin. Administer drugs at least 2 hours apart and flush line well between infusions
Check for drug interactions prior to use
